PharmaNews.eu
  • Home
  • Business
  • R&D
  • EC
  • EMA
  • Events
  • Open Calls

Pfizer

Pfizer

PfizerFounded in 1849, Pfizer is the world's largest research-based pharmaceutical company. Pfizer is taking new approaches to advancing better health as it discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. Pfizer also partners with healthcare providers, governments and local communities around the world to expand access to medicines and to provide better quality health care and health system support. At Pfizer, more than 84,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide. For more information visit www.pfizer.com.

Pfizer RSS Channel

Filters
List of articles in category Pfizer
Title Published Date
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures 28 May 2019
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis 22 April 2019
Pfizer initiates phase 2b/3 clinical trial for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with moderate to severe alopecia areata 09 January 2019
Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV™ (bevacizumab) 14 December 2018
Pfizer reaches a global agreement with AbbVie 04 December 2018
Pfizer to award more than $3 million in grants to further breast cancer research 04 October 2018
Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy 05 September 2018
Pfizer to organize for future growth 13 July 2018
BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia 07 July 2017
Pfizer receives exclusive commercialization rights in Europe for CRESEMBA 14 June 2017
Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia 21 April 2017
XELJANZ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis 27 March 2017
IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery 02 December 2016
Strengthening NHS research: Patients to access more new treatments through clinical trials 31 October 2013
Pfizer statement on PhRMA-EFPIA principles for responsible clinical trial data sharing 26 July 2013
ELIQUIS® (apixaban) receives CHMP positive opinion for the prevention of stroke and systemic embolism 21 September 2012
Pfizer receives EU marketing authorization for INLYTA® (Axitinib) 04 September 2012
European Medicines Agency accepts regulatory submission for bazedoxifene/conjugated estrogens 19 July 2012
Pfizer's Vyndaqel® (tafamidis) First Therapy Approved in the European Union 16 November 2011
Pfizer Receives European Approval to Extend Use of Prevenar 13 30 October 2011

Page 2 of 4

  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next
  • End
Build the future of health through collaboration & innovation
  1. You are here:  
  2. Home
  3. Pfizer

About

  • Home
  • Terms and Conditions
  • Contact

Advertise

Top News Channels

  • Business
  • Research
  • EMA
  • Events

Follow us

Didn't we got you connected? If not, please note the following magic buttons:

  • Facebook
  • Twitter
  • RSS 2.0
  • Atom 1.0

Newsletter

Stay updated on the latest Pharma News. Subscribe now, it's free!

Copyright © 2021 PharmaNews.eu. All Rights Reserved.